Bimekizumab given by vein or by injection in psoriatic arthritis and axial spondyloarthritis
Compares bimekizumab given by vein or injection in adults with active joint disease.
Plain-language title generated from the registry record
Registry title: A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Key facts
- Where
- Košice and Piešťany, SlovakiaSee the 3 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active psoriatic arthritis or active axial spondyloarthritis who can have bimekizumab treatment. It compares bimekizumab given into a vein with bimekizumab given as an injection under the skin.
- Age
- 18 years or older, and able to give legal consent.
- Sex
- All sexes can join.
- Disease stage
- Active psoriatic arthritis (PsA) or active axial spondyloarthritis (axSpA).
- Earlier treatment
- People must have had no biologic disease-modifying anti-rheumatic drug (bDMARD) before, or must have stopped it at least 3 months or 5 half-lives ago.
Main reasons for not taking part
- Serious organ disorders (for example heart, liver, kidney, gut or nervous system)
- Severe psychiatric problems or substance abuse in the past year
- Recent or long-lasting infections, including tuberculosis (TB) or nontuberculous mycobacterium (NTMB)
- Other inflammatory diseases (for example rheumatoid arthritis, lupus, inflammatory bowel disease)
- Recent live vaccine (within 8 weeks), BCG vaccine (within 1 year) or GLP-1 agonist use (within 28 weeks)
Read by machine on 9 November 2026.
Where in Slovakia
- Pa0019 601Košice, SlovakiaTaking people
- Pa0019 602Košice, SlovakiaTaking people
- Pa0019 603Piešťany, SlovakiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UCB Biopharma SRL
- Trial code
- NCT07290036
- Record updated
- 6 November 2026
- Original description
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.Read full original descriptionShow less
An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
Inclusion: Be 18+ years old and legally able to consent; Have active psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), suitable for bimekizumab treatment; Weigh between 45-100 kg (females) or 50-100 kg (males); Be biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve or have stopped bDMARDs ≥3 months or 5 half-lives ago.
Exclusion: Recent live vaccines (within 8 weeks) or Bacillus Calmette-Guerin (BCG) (within 1 year); Serious organ system disorders (e.g., heart, liver, kidney, gastrointestinal, neuro); Severe psychiatric issues or substance abuse in the past year; Recent or chronic infections, including tuberculosis (TB) or nontuberculous mycobacterium (NTMB); Other inflammatory diseases (e.g., rheumatoid arthritis (RA), lupus, inflammatory bowel disease (IBD)); Recent use of glucagon-like peptide-1 (GLP-1) agonists (within 28 weeks).